Japan's health ministry is one of the world's toughest when it comes to demanding truth in advertising. The newest target of its scrutiny is Takeda Pharmaceutical, which is now admitting it may have mis-marketed its hypertension drug Blopress. Takeda's CEO, Yasuchika Hasegawa, told reporters at a news conference on Monday that the company used "inappropriate expressions" to advertise the drug, according to The Wall Street Journal.
A new public health partnership called the Global Health Innovative Technology Fund is doling out $5.7 million in grants to 6 programs across the globe to boost research and development of promising vaccines against malaria, tuberculosis and Chagas disease.
Research presented at the International Conference on Molecular Targets and Cancer Therapeutics this week in Boston could point the way to new therapies to treat pancreatic cancer.
The Department of Justice has rounded up billions of dollars from drugmakers in one whistleblower case after another. But some recent court decisions suggest that whistleblowers could face a higher bar for getting their cases heard. Now, as Pharmalot reports, the U.S. Supreme Court is asking the Solicitor General for its opinion on the subject.
The jury has spoken in the latest Actos trial, and the verdict was this: Takeda Pharmaceutical didn't properly flag the risks of its diabetes drug, and Takeda should pay $1.7 million to the family of Diep An, an Actos patient who died of bladder cancer.
Takeda CEO Yasuchika Hasegawa insists that the company is righting itself and that its bet on emerging markets will be key. He is upping that wager with a new operation in the rapidly-growing Latin American market, where the company already has a significant foothold.
Major tech and services firms would love for pharma to give cloud computing a wholehearted embrace, but the reality is that cloud software and services have trickled into the spending plans of drugmakers as they slowly warm up to web-based systems.
On the heels of a big earnings shortfall, the Japanese drugmaker's CEO is touting its cost-cutting programs and growth in emerging markets.
Japan's drugmakers aren't any more immune from generic competition than U.S. pharma companies are. Still the country's second- and third-largest drugmakers are predicting sales growth this year, even as low-cost copies drain away sales of their key products. New drugs are coming in to pick up the slack, the companies said.
CEO Deborah Dunsire is retiring from Millennium, the unit Takeda bought about 5 years ago, as Millennium's oncology R&D is rolled up into the parent company's global research organization.